Roger Kang is vice president of business development at Princeton BioMeditech Corporation (PBM), which specializes in point-of-care tests related to fertility, infectious disease, tumors, cardiology, and veterinary and environmental diagnostics. The company’s rapid COVID-19 test — which Mr. Kang provided to UC Berkeley and the companies of UCBF fellow trustees at a significant discount — was the first of its kind to provide a combination rapid COVID-19 and influenza A&B test. Mr. Kang has served on the East Coast Chancellor’s Council since 2014, including three years as its co-chair. He worked to refine the council’s focus on fundraising, recruiting new members and making peer introductions. He is a UC Berkeley Foundation (UCBF) trustee, serving as vice chair of the nominations committee and as a member of the finance committee. In 2012, Mr. Kang and his family established a fellowship to support high-achieving doctoral students studying biotechnology at Berkeley. He is also working to help Berkeley launch an entirely new master’s program in biotechnology that emphasizes entrepreneurship, technology innovation, and interdisciplinary work. Mr. Kang is a Builder of Berkeley.
Vice President, Business Development, Princeton BioMeditech Corporation